Compare Sana Biotechnology Inc (SANA) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Tilray Brands Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Tilray Brands Inc trades at $4.27 (market cap $524.07M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| SANA | TLRY | |
|---|---|---|
Market Cap | $873.84M | $524.07M |
Sector | Health | Health |
52-Week High | $5.92 | $21.00 |
52-Week Low | $2.68 | $4.23 |
Enterprise Value | $848.03M | $621.22M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
TLRY trades at $4.23, down 1.63% with bearish technical signals. The company reported revenue growth to $821.31M in 2025 but faces severe profitability challenges with a net loss of $2.19B and negative margins. Recent expansion includes medical cannabis launches in Panama and strategic acquisitions, while analyst consensus shows cautious sentiment with 65% hold ratings.
The outlook remains challenging due to persistent losses and high debt levels, though expansion initiatives and potential regulatory changes offer long-term opportunities. Key risks include execution on profitability, competitive pressures, and cannabis regulatory uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
